Biofrontera Inc. (NASDAQ:BFRI – Get Free Report) saw a large increase in short interest in the month of October. As of October 30th, there was short interest totaling 189,627 shares, an increase of 83.8% from the October 15th total of 103,148 shares. Currently, 1.4% of the shares of the stock are sold short. Based on an average trading volume of 146,358 shares, the short-interest ratio is presently 1.3 days.
Biofrontera Stock Performance
BFRI traded down $0.23 on Friday, hitting $0.70. The company had a trading volume of 875,774 shares, compared to its average volume of 148,265. The company has a debt-to-equity ratio of 0.78, a current ratio of 1.18 and a quick ratio of 1.08. The company’s fifty day moving average price is $1.02 and its 200 day moving average price is $1.03. The stock has a market cap of $10.40 million, a price-to-earnings ratio of -1.56 and a beta of 0.88. Biofrontera has a 1-year low of $0.55 and a 1-year high of $1.66.
Biofrontera (NASDAQ:BFRI – Get Free Report) last posted its earnings results on Friday, November 13th. The company reported ($0.42) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.31). The firm had revenue of $9.07 million during the quarter, compared to analyst estimates of $8.50 million. Biofrontera had a negative net margin of 13.78% and a negative return on equity of 145.81%.
Institutional Trading of Biofrontera
Analyst Upgrades and Downgrades
Several research analysts recently weighed in on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Biofrontera in a research note on Tuesday, October 13th. Zacks Research upgraded Biofrontera from a “strong sell” rating to a “hold” rating in a report on Monday, August 3rd. Finally, Wall Street Zen cut shares of Biofrontera from a “buy” rating to a “hold” rating in a report on Sunday, September 20th. One research analyst has rated the stock with a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Biofrontera has an average rating of “Reduce”.
View Our Latest Report on Biofrontera
About Biofrontera
Biofrontera Inc. is a biopharmaceutical company focused on dermatology and the commercial development of prescription products for treating skin conditions. Its business is primarily centered on the U.S. market. The company’s main product is Ameluz, a topical gel containing aminolevulinic acid hydrochloride. It is used with Biofrontera’s BF-RhodoLED light device in photodynamic therapy to treat certain actinic keratoses, precancerous lesions that can develop on sun-damaged skin. Biofrontera’s products combine a topical treatment with a specialized light source, which activates the treatment during a clinical procedure.
See Also
- Five stocks we like better than Biofrontera
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Biofrontera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biofrontera and related companies with MarketBeat.com's FREE daily email newsletter.
